FGFR3 and breast cancer: By analyzing the GDSC database, the FARG signature predicted that irrespective of carrying FGFR3 alterations or not, BC patients with a lower FARG score were likely to be more sensitive to methotrexate and tipifarnib, whereas those with a higher FARG score seemed to have higher sensitivities to bleomycin, cisplatin, docetaxel, paclitaxel, vinblastine, and vorinostat.